| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/22/2004 | WO2004007457A2 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | WO2004007454A1 Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| 01/22/2004 | WO2004007453A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| 01/22/2004 | WO2004006941A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| 01/22/2004 | WO2004006938A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | WO2004006918A1 Phenylalanine enamide derivatives containing a spiro`3.5!non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | WO2004006902A1 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | WO2004006901A1 Gastrointestinal compositions comprising gaba derivatives |
| 01/22/2004 | WO2004006899A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | WO2004006853A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | WO2004006692A1 Improved bulking agent compositions |
| 01/22/2004 | WO2004006662A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARα GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 01/22/2004 | WO2003097665A3 Mid 241 receptor, a novel g-protein coupled receptor |
| 01/22/2004 | WO2003082813A3 Improvements in pharmaceutical compositions |
| 01/22/2004 | WO2003072022A3 Oral trimethobenzamide formulations and methods |
| 01/22/2004 | WO2003066087A3 Kinases involved in the regulation of energy homeostasis |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003060521A3 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2003045316A3 Polynucleotide therapy |
| 01/22/2004 | WO2003024395A8 Linked biaryl compounds |
| 01/22/2004 | WO2003024390A3 Hydroxyeicosenoic acid analogs |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2002092573A3 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | US20040014973 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines |
| 01/22/2004 | US20040014971 N-(4-(4-(2-oxo-1-phenyl-2-((2,2,2-trifluoroethyl)amino)ethyl)-1 -piperazinyl)-phenyl)-4'-(trifluoromethyl)-(1,1'-biphenyl)-2-carboxamide for treatment of obesity, diabetes, and cardiovascular disorders; decreases apoplioprotein secretion |
| 01/22/2004 | US20040014956 For increasing nuclease resistance of antisense sequences |
| 01/22/2004 | US20040014899 The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, |
| 01/22/2004 | US20040014809 Novel n-( 2-phenyl-3-aminopropyl)naphtamides |
| 01/22/2004 | US20040014793 Stability in blood |
| 01/22/2004 | US20040014788 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht receptor agonists |
| 01/22/2004 | US20040014783 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 01/22/2004 | US20040014782 Combination therapy for the treatment of diseases involving inflammatory components |
| 01/22/2004 | US20040014771 Synergistic mixture of antiserotonin agents and serotonin reuptake inhibitors; analgesics; irritable bowel syndrome |
| 01/22/2004 | US20040014769 Central nervous system disorders; antidepressants; anxiolytic agents; eating disorders |
| 01/22/2004 | US20040014763 beta-sheet mimetics and composition and methods relating thereto |
| 01/22/2004 | US20040014762 Pyrrolopyridazine compounds |
| 01/22/2004 | US20040014760 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 01/22/2004 | US20040014754 Urea substituted imidazoquinolines |
| 01/22/2004 | US20040014747 CRF receptor antagonists and methods relating thereto |
| 01/22/2004 | US20040014743 Mbreast and prostate anticancer agents; viricides; alopecia |
| 01/22/2004 | US20040014723 Calcilytic compounds |
| 01/22/2004 | US20040014685 Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/22/2004 | US20040014684 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic |
| 01/22/2004 | US20040014653 Oral diseases; skin disorders; aging resistance |
| 01/22/2004 | US20040014634 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals |
| 01/22/2004 | US20040014219 Comprises expression vector coding fusion protein associated cell proliferation and/or differentiation; gene therapy; animal model for disease |
| 01/22/2004 | US20040014132 Comprises immunoglobulins which binds and neutralizes chemoattractants (eotaxin) for modulating inflammatory response; antiinflammtory agents; antiallergens |
| 01/22/2004 | US20040014111 Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases |
| 01/22/2004 | US20040014057 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013706 Stress and radiation resistance; antiallergens; antiinflammatory agents |
| 01/22/2004 | US20040013676 Administering dosage of mature dendritic cells in carrier |
| 01/22/2004 | US20040013642 Interferon therapeutic effect-potentiating agents |
| 01/22/2004 | DE10230381A1 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen Use of inhibitors of alanyl-aminopeptidase, and pharmaceutical preparations comprising them |
| 01/22/2004 | CA2492716A1 Brachyspira hyodysenteriae vaccine |
| 01/22/2004 | CA2492694A1 Therapeutic or prophylactic agent for preventing nausea and vomiting |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492430A1 Phenylalanine enamide derivatives |
| 01/22/2004 | CA2492381A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | CA2492374A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | CA2492355A1 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492045A1 Substituted amine derivatives and methods of use |
| 01/22/2004 | CA2491797A1 Gastrointestinal compositions |
| 01/22/2004 | CA2491721A1 Gastrointestinal compositions comprising gaba derivatives |
| 01/22/2004 | CA2491655A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/22/2004 | CA2490666A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382606A2 8-azabicyclo[3.2.1]octane derivatives and their use as anticholinergics |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382603A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF |
| 01/21/2004 | EP1382343A1 Combination therapy to treat hepatitis B virus |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382333A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria |
| 01/21/2004 | EP1382263A2 Use of calcium in acidic oral compositions for the reduction of tooth erosion caused by acid |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381681A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381630A2 Vhh single heavy chain antibody and a method for its preparation in a mammal |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381620A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 01/21/2004 | EP1381606A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381455A1 Stable aqueous colloidal dispersion, method for preparing same |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381386A2 Novel mixtures of microbial enzymes |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381364A1 Use of mangafodipir for treating oxidative stress effects |
| 01/21/2004 | EP1381354A2 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |